Login
Surrozen, Inc. logo

Surrozen, Inc.

surrozen.com

What Do They Do?

Develops antibody-based drug candidates that target the Wnt tissue-repair pathway for serious eye diseases, including retinal conditions.

How Do They Make Money?

It receives fees for antibody-discovery services over time; licensing arrangements can also bring upfront and milestone payments and royalties on licensed-product sales.

revenue
SegmentShareRevenue
Research service revenue
Recurring

100%
Collaboration and license revenue
Licensed
0.0%

Who Are Their Customers?

Works directly with TCGFB on antibody-discovery services and licenses Fzd4 antibody candidates to Boehringer Ingelheim, which handles further development, manufacturing and commercialization.

Do Revenues Turn Into Profits?

No. It lost $242M in FY2025.

Operating income, FY2025
−1211% of revenue
▼ −65% (Loss) vs FY2024 (−$25.5M, −240%)
Net income, FY2025
−6961% of revenue
▼ −281% (Loss) vs FY2024 (−$63.6M, −597%)
Free cash flow, FY2025
−874% of revenue
▼ −72% (Loss) vs FY2024 (−$17.7M, −166%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $983K in Q3 FY2025
Net income
▼ −81% (Loss)
vs −$71.6M in Q3 FY2025

Focus on eye disease The company described programs across multiple organs, including intestine and liver, and Wnt and R-spondin approaches. It now focuses on ophthalmology, with candidates and research programs aimed at eye diseases.

Revenue over time
Research service revenue Collaboration and license revenue
$20M$10M$0

Who Do They Compete With?

Competes with Roche, Regeneron, Novartis, Bayer, AbbVie, Boehringer Ingelheim, Amgen, Merck, Sanofi, Eli Lilly, and Samsung Bioepis

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support